Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BBOX1 | O75936 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | GMNN | O75496 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | HBB | P68871 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GRK2 | P25098 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15547776 | 0.92 | BBOX1 (0.64) | BBOX1LMNAGMNNALDH1A1TP53 | |
| SCHEMBL26789436 | 0.81 | BBOX1 (0.73) | BBOX1LMNAMEN1POLBGRK2 | |
| SCHEMBL25663649 | 0.81 | BBOX1 (0.73) | BBOX1LMNAGMNNALDH1A1TP53 | |
| SCHEMBL16211685 | 0.79 | BBOX1 (0.64) | BBOX1LMNAGMNNALDH1A1TP53 | |
| SCHEMBL9107831 | 0.79 | BBOX1 (0.64) | BBOX1LMNAGMNNALDH1A1TP53 | |
| SCHEMBL21408834 | 0.79 | BBOX1 (0.64) | BBOX1LMNAGMNNALDH1A1TP53 | |
| SCHEMBL15380501 | 0.79 | APP (0.54) | BBOX1LMNAHTT | |
| Ethyl Dimethyl Ammonio Propane Sulfonate SCHEMBL17699044 | 0.78 | BBOX1 (1.00) | BBOX1LMNAGMNNALDH1A1TP53 | |
| SCHEMBL60617 | 0.78 | BBOX1 (0.68) | BBOX1KMT2AHTT | |
| SCHEMBL10937740 | 0.78 | BBOX1 (0.68) | BBOX1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027047-A1 | HYDROGELS FOR CELL THERAPY | ADOCIA (FR) | 2026-01-29 | — | — | US | disclosed |
| EP-4554983-A1 | HYDROGELS FOR CELL THERAPY | Adocia (FR) | 2025-05-21 | — | — | EP | disclosed |
| WO-2025011419-A1 | LINKER-DRUG MOLECULE AND ANTIBODY DRUG CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海诗健生物科技有限公司 | 2025-01-16 | — | — | WO | disclosed |
| CN-119264213-A | Linker-drug molecule and antibody drug conjugate, and preparation method and application thereof | 上海诗健生物科技有限公司 | 2025-01-07 | — | — | CN | disclosed |
| US-20240018276-A1 | ZWITTERIONICALLY MODIFIED POLYMERS AND HYDROGELS | UNIV CORNELL (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2024013355-A1 | HYDROGELS FOR CELL THERAPY | ADOCIA (FR) | 2024-01-18 | — | — | WO | disclosed |
| WO-2024013353-A1 | HYDROGELS FOR CELL THERAPY | ADOCIA (FR) | 2024-01-18 | — | — | WO | disclosed |
| EP-4306548-A1 | HYDROGELS FOR CELL THERAPY | Adocia (FR) | 2024-01-17 | — | — | EP | disclosed |
| EP-4306550-A1 | HYDROGELS FOR CELL THERAPY | Adocia (FR) | 2024-01-17 | — | — | EP | disclosed |
| US-10597409-B2 | Water-soluble triazapyridinophane-based complexing agents and corresponding fluorescent lanthanide complexes | CISBIO BIOASSAYS (FR) | 2020-03-24 | — | — | US | disclosed |
| EP-3386974-B1 | WATER-SOLUBLE TRIAZAPYRIDINOPHANE-BASED COMPLEXING AGENTS AND CORRESPONDING FLUORESCENT LANTHANIDE COMPLEXES | CISBIO BIOASSAYS (FR) | 2020-02-05 | — | — | EP | disclosed |
| US-20180362549-A1 | WATER-SOLUBLE TRIAZAPYRIDINOPHANE-BASED COMPLEXING AGENTS AND CORRESPONDING FLUORESCENT LANTHANIDE COMPLEXES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-12-20 | — | — | US | disclosed |
| EP-3386974-A1 | WATER-SOLUBLE TRIAZAPYRIDINOPHANE-BASED COMPLEXING AGENTS AND CORRESPONDING FLUORESCENT LANTHANIDE COMPLEXES | CISBIO BIOASSAYS (FR) | 2018-10-17 | — | — | EP | disclosed |
| US-10040874-B2 | Multifunctional and multicoordinating amphiphilic polymer ligands for interfacing semiconducting, magnetic, and metallic nanocrystals with biological systems | The Florida State University Research Foundation, Inc. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10040874-B2 | Multifunctional and multicoordinating amphiphilic polymer ligands for interfacing semiconducting, magnetic, and metallic nanocrystals with biological systems | The Florida State University Research Foundation, Inc. (US) | 2018-08-07 | — | — | US | disclosed |
| WO-2017098180-A1 | WATER-SOLUBLE TRIAZAPYRIDINOPHANE-BASED COMPLEXING AGENTS AND CORRESPONDING FLUORESCENT LANTHANIDE COMPLEXES | CISBIO BIOASSAYS (FR) | 2017-06-15 | — | — | WO | disclosed |
| US-20170058056-A1 | MULTIFUNCTIONAL AND MULTICOORDINATING AMPHIPHILIC POLYMER LIGANDS FOR INTERFACING SEMICONDUCTING, MAGNETIC, AND METALLIC NANOCRYSTALS WITH BIOLOGICAL SYSTEMS | The Florida State University Research Foundation, Inc. | 2017-03-02 | — | — | US | disclosed |
| US-8846739-B2 | TGR5 agonists | EXELIXIS PATENT COMPANY LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130303505-A1 | TGR5 AGONISTS | EXELIXIS PATENT COMPANY LLC | 2013-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018276-A1 | ZWITTERIONICALLY MODIFIED POLYMERS AND HYDROGELS | CHRM1, CHRM2, F12 | BBOX1 3853/4885LMNA 2220/4885GMNN 1617/4885 |
| US-20260027047-A1 | HYDROGELS FOR CELL THERAPY | IAPP, ITGA1, ITGB1 | BBOX1 2412/4885LMNA 4087/4885GMNN 3508/4885 |
| US-10597409-B2 | Water-soluble triazapyridinophane-based complexing agents and corresponding fluorescent lanthanide complexes | GSTA1, CLIC1, SLC40A1 | BBOX1 691/4885LMNA 2362/4885GMNN 479/4885 |
| US-20180362549-A1 | WATER-SOLUBLE TRIAZAPYRIDINOPHANE-BASED COMPLEXING AGENTS AND CORRESPONDING FLUORESCENT LANTHANIDE COMPLEXES | GSTA1, CLIC1, SLC40A1 | BBOX1 691/4885LMNA 2362/4885GMNN 479/4885 |
| US-20130303505-A1 | TGR5 AGONISTS | GCGR, NPY5R, TBXA2R | BBOX1 3048/4885LMNA 2547/4885GMNN 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.